drugset / Trial / NCT00755183

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183

Phase 2 Completed 60 enrolled ORA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 0.03 % Other

Indications